Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorMassachusetts General Hospital
About this trial
This neuroimaging study is a clinical trial investigating the effectiveness of intermittent theta-burst transcranial magnetic stimulation (iTBS-TMS) to the inferior parietal lobule (IPL) in reducing suicide risk in patients with major depressive episode (MDE) or borderline personality disorder (BPD).
Eligibility criteria
Qualifiers
18-65 years of age
Diagnosed with BPD or MDE
Chief complaint of suicidal thoughts and behaviors
Disqualifiers
Neurological conditions with known structural brain lesion
Prior neurosurgical procedure
Metal in the body that is ferromagnetic or metal injury to the eyes
Epilepsy
Trial design
Treatments tested in this trial
- Intermittent Theta Burst Transcranial Magnetic Stimulation (Active)
- Intermittent Theta Burst Transcranial Magnetic Stimulation (Sham)
Treatment groups
80 Participants
are divided into 4 treatment groupsLocations
1Massachusetts General Hospital02129, BostonMassachusetts, United States
Sponsors and collaborators
Massachusetts General Hospital
Lead sponsor
Source ClinicalTrials.gov